Elizabeth (Tess) Saarel, MD, discusses what steps pediatricians can take to help identify children with inherited heart disease and congenital heart defects who are at risk for SCD.Read More
The goal of thyroid hormone replacement is to achieve clinical and biochemical euthyroidism. Unless there is pituitary compromise, TSH continues to be the most reliable marker of adequacy of thyroid hormone replacement, says Cleveland Clinic’s Christian Nasr. MD.
Anu Suri, MD, staff in the Respiratory Institute, answers three questions about the moral responsibility of physicians to talk with patients about end-of-life care.
ECNO Kelly Hancock discusses how delegation and empowerment are vital to successful nurse leadership. These skills help leaders enhance efficiency, further develop teams, improve patient outcomes, and more.
Stem cells show potential as disease-modifying and restorative therapy in a range of nervous system disorders, but they’re far from ready for prime time. An expert outlines the reasons why and the road ahead.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The new-generation S1P receptor modulator shows impressive effects on relapse rate and MRI lesion activity with no significant safety concerns. The trial’s lead investigator looks ahead to what’s next.
A Cleveland Clinic interventional cardiologist puts the SURTAVI trial in context and speaks to what’s needed to help intermediate-risk patients make the best choice between two good AVR options.
Discover how Cleveland Clinic physicians successfully treated a patient presenting with both the uncommon infection uvulitis as well as epiglottitis.
Physicians, scientists and advanced practice providers from virtually every medical specialty and scientific field heard their colleagues on the leading edge of this work highlight the hopes and challenges of precision medicine for the nearly 50 million people in the U.S. with disorders of immunity.
A new whole-exome sequencing study uncovers the dynamics of genetic alterations during progression of MDS to more aggressive acute leukemia and clarifies the impact of specific genetic defects on expected clinical behavior.